The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology
Open accessAbstract
The study of botulinum neurotoxins (BoNT) is rapidly progressing in many aspects. Novel BoNTs are being discovered owing to next generation sequencing, but their biologic and pharmacological properties remain largely unknown. The molecular structure of the large protein complexes that the toxin forms with accessory proteins, which are included in some BoNT type A1 and B1 pharmacological preparations, have been determined. By far the largest effort has been dedicated to the testing and validation of BoNTs as therapeutic agents in an ever increasing number of applications, including pain therapy. BoNT type A1 has been also exploited in a variety of cosmetic treatments, alone or in combination with other agents, and this specific market has reached the size of the one dedicated to the treatment of medical syndromes. The pharmacological properties and mode of action of BoNTs have shed light on general principles of neuronal transport and protein-protein interactions and are stimulating basic science studies. Moreover, the wide array of BoNTs discovered and to be discovered and the production of recombinant BoNTs endowed with specific properties suggest novel uses in therapeutics with increasing disease/symptom specifity. These recent developments are reviewed here to provide an updated picture of the biologic mechanism of action of BoNTs, of their increasing use in pharmacology and in cosmetics, and of their toxicology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–228 of 228
Megighian, A., Zordan, M. A., Pantano, S., Scorzeto, M., Rigoni, M., Zanini, D., Rossetto, O., & Montecucco, C. (2013) · Journal of Cell Science · doi:10.1242/jcs.123802 · Cited by 45
Self-citationThe structure and function of presynaptic endosomes
Jähne, S., Rizzoli, S. O., & Helm, M. S. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.04.017 · Cited by 44
Fern�ndez-Salas, E., Ho, H., Garay, P. E., Steward, L. E., & Aoki, K. R. (2004) · Movement Disorders · doi:10.1002/mds.20006 · Cited by 44
Couesnon, A., Molgó, J., Connan, C., & Popoff, M. R. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002583 · Cited by 44
Zanetti, G., Tehran, D. A., Pirazzini, M., Binz, T., Shone, C. C., Fillo, S., Lista, F. R., Rossetto, O., & Montecucco, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.09.023 · Cited by 42
Self-citationPharmacotherapy of allergic rhinitis: a pharmaco‐economic approach
Simoens, S., & Laekeman, G. (2008) · Allergy · doi:10.1111/j.1398-9995.2008.01909.x · Cited by 41
Re-Assembled Botulinum Neurotoxin Inhibits CNS Functions without Systemic Toxicity
Ferrari, E., Maywood, E. S., Restani, L., Caleo, M., Pirazzini, M., Rossetto, O., Hastings, M. H., Niranjan, D., Schiavo, G., & Davletov, B. A. (2011) · Toxins · doi:10.3390/toxins3040345 · Cited by 38
Self-citationBotulinum neurotoxins: new questions arising from structural biology
Kammerer, R. A., & Benoit, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.009 · Cited by 37
Novel Ganglioside-mediated Entry of Botulinum Neurotoxin Serotype D into Neurons
Kroken, A. R., Karalewitz, A., Fu, Z., Kim, J. P., & Barbieri, J. T. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.254086 · Cited by 36
Vagin, O., Tokhtaeva, E., Garay, P. E., Souda, P., Bassilian, S., Whitelegge, J. P., Lewis, R., Sachs, G. M., Wheeler, L. A., Aoki, R., et al. (2014) · Journal of Cell Science · doi:10.1242/jcs.146324 · Cited by 36
Peng, L., Adler, M., Demogines, A., Borrell, A., Liu, H., Tao, L., Tepp, W. H., Zhang, S., Johnson, E. A., Sawyer, S. L., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004177 · Cited by 36
Botulinum toxin A does not alter capsaicin-induced pain perception in human skin
Schulte‐Mattler, W., Opatz, O. S., Blersch, W., et al. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.03.023 · Cited by 35
A Novel Inhibitor Prevents the Peripheral Neuroparalysis of Botulinum Neurotoxins
Tehran, D. A., Zanetti, G., Leka, O., Lista, F. R., Fillo, S., Binz, T., Shone, C. C., Rossetto, O., Montecucco, C., Paradisi, C., et al. (2015) · Scientific Reports · doi:10.1038/srep17513 · Cited by 33
Self-citationSikorra, S., Litschko, C., Müller, C., Thiel, N., Galli, T., Eichner, T., & Binz, T. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.10.024 · Cited by 32
Berntsson, R. P. ‐., Peng, L., Svensson, L. M., Dong, M., & Stenmark, P. (2013) · Structure · doi:10.1016/j.str.2013.06.026 · Cited by 32
Mahrhold, S., Bergström, T. B., Stern, D., Dorner, B. G., Åstot, C., & Rummel, A. (2016) · Biochemical Journal · doi:10.1042/bcj20160439 · Cited by 31
Band, P. A., Blais, S. P., Neubert, T. A., Cardozo, T. J., & Ichtchenko, K. (2010) · Protein Expression and Purification · doi:10.1016/j.pep.2009.12.013 · Cited by 30
Quantal Neurotransmitter Release and the Clostridial Neurotoxins’ Targets
Poulain, B., Molgó, J., & Thesleff, S. (1995) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-85173-5_11 · Cited by 29
Albanese, A., & Lalli, S. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283550c22 · Cited by 27
Other indications of botulinum toxin therapy
Jost, W. H. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01448.x · Cited by 27
Fischer, A. E. (2012) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-45790-0_6 · Cited by 26
Beske, P. H., Scheeler, S. M., Adler, M., & McNutt, P. M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00159 · Cited by 25
Botulinum Neurotoxins Can Enter Cultured Neurons Independent of Synaptic Vesicle Recycling
Pellett, S., Tepp, W. H., Scherf, J. M., & Johnson, E. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133737 · Cited by 22
Cousin, M. A. (2014) · The Neuroscientist · doi:10.1177/1073858414542251 · Cited by 16
Sorbo, F. D., & Albanese, A. (2015) · Toxicon · doi:10.1016/j.toxicon.2015.09.010 · Cited by 12
Buonocore, M., Demartini, L., Mandrini, S., Dall’Angelo, A., & Toffola, E. D. (2016) · PM&R · doi:10.1016/j.pmrj.2016.10.014 · Cited by 9
Clinical Use of Botulinum Neurotoxin: Neuromuscular Disorders
Guidubaldi, A., Bentivoglio, A. R., & Albanese, A. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0261-3_3 · Cited by 3
Nidogens are therapeutic targets for the prevention of tetanus
Bercsényi, K., Schmieg, N., Bryson, J. B., Wallace, M., Caccin, P., Golding, M., Zanotti, G., Greensmith, L., Nischt, R., & Schiavo, G. (2014) · Science · doi:10.1126/science.1258138 · Cited by 1
Cited by
Skeletal muscle: A review of molecular structure and function, in health and disease
Mukund, K., & Subramaniam, S. (2020) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1462 · Cited by 664
Balint, B., Mencacci, N. E., Valente, E. M., Pisani, A., Rothwell, J., Jankovic, J., Vidailhet, M., & Bhatia, K. P. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0023-6 · Cited by 344
Mechanisms of Botulinum Toxin Type A Action on Pain
Matak, I., Bölcskei, K., Bach-Rojecky, L., & Helyes, Z. (2019) · Toxins · doi:10.3390/toxins11080459 · Cited by 267
The Epigenetic Dimension of Protein Structure Is an Intrinsic Weakness of the AlphaFold Program
Azzaz, F., Yahi, N., Chahinian, H., & Fantini, J. (2022) · Biomolecules · doi:10.3390/biom12101527 · Cited by 53
Joensuu, M., Syed, P., Saber, S. H., Lanoue, V., Wallis, T. P., Rae, J., Blum, A., Gormal, R. S., Small, C., Sanders, S., et al. (2023) · The EMBO Journal · doi:10.15252/embj.2022112095 · Cited by 34
Metadata
- Authors
- Pirazzini, M., Rossetto, O., Eleopra, R., & Montecucco, C.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 69
- Issue
- 2
- Pages
- 200-235
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2598060151
- Cited by
- 768
- References
- 228
- FWCI
- 38.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.